| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Inflammation, Wyeth Research, Cambridge, MA 02140;
Exploratory Drug Safety, Wyeth Research, Andover, MA 01810; and
Department of Genetics, Wyeth Research, Andover, MA 01810
Experimental autoimmune encephalomyelitis (EAE), a T cell-mediated inflammatory disease of the CNS, is a rodent model of human multiple sclerosis. IL-23 is one of the critical cytokines in EAE development and is currently believed to be involved in the maintenance of encephalitogenic responses during the tissue damage effector phase of the disease. In this study, we show that encephalitogenic T cells from myelin oligodendrocyte glycopeptide (MOG)-immunized wild-type (WT) mice caused indistinguishable disease when adoptively transferred to WT or IL-23-deficient (p19 knockout (KO)) recipient mice, demonstrating that once encephalitogenic cells have been generated, EAE can develop in the complete absence of IL-23. Furthermore, IL-12/23 double-deficient (p35/p19 double KO) recipient mice developed EAE that was indistinguishable from WT recipients, indicating that IL-12 did not compensate for IL-23 deficiency during the effector phase of EAE. In contrast, MOG-specific T cells from p19KO mice induced EAE with delayed onset and much lower severity when transferred to WT recipient mice as compared with the EAE that was induced by cells from WT controls. MOG-specific T cells from p19KO mice were highly deficient in the production of IFN-
, IL-17A, and TNF, indicating that IL-23 plays a critical role in development of encephalitogenic T cells and facilitates the development of T cells toward both Th1 and Th17 pathways.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Address correspondence and reprint requests to Dr. Paresh Thakker, Department of Inflammation, Wyeth Research, 200 Cambridgepark Drive, Cambridge, MA 02140. E-mail address: pthakker{at}wyeth.com
2 M.W.L. and W.K. contributed equally to this research.
3 Current address: Genzyme Drug Discovery and Development, Waltham, MA 02451.
4 J.P.L. and S.M. contributed equally to this research.
5 Abbreviations used in this paper: EAE, experimental autoimmune encephalomyelitis; MS, multiple sclerosis; MOG, myelin oligodendrocyte glycoprotein; CBA, cytometric bead assay; WT, wild type; KO, knockout mice; DKO, double KO; ES, embryonic stem; BAC, bacterial artificial chromosome.
This article has been cited by other articles:
|
|
 |
|
  K. A. Staschke, S. Dong, J. Saha, J. Zhao, N. A. Brooks, D. L. Hepburn, J. Xia, M. F. Gulen, Z. Kang, C. Z. Altuntas, et al. IRAK4 Kinase Activity Is Required for Th17 Differentiation and Th17-Mediated Disease J. Immunol., July 1, 2009; 183(1): 568 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Ingram, J. D. Isaacs, G. Kaur, D. E. Lowther, C. J. Reynolds, R. J. Boyton, J. Collinge, G. S. Jackson, and D. M. Altmann A role of cellular prion protein in programming T-cell cytokine responses in disease FASEB J, June 1, 2009; 23(6): 1672 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Guo, D. Cobb, and R. B. Smeltz T-bet Inhibits the In Vivo Differentiation of Parasite-Specific CD4+ Th17 Cells in a T Cell-Intrinsic Manner J. Immunol., May 15, 2009; 182(10): 6179 - 6186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Skarica, T. Wang, E. McCadden, D. Kardian, P. A. Calabresi, D. Small, and K. A. Whartenby Signal Transduction Inhibition of APCs Diminishes Th17 and Th1 Responses in Experimental Autoimmune Encephalomyelitis J. Immunol., April 1, 2009; 182(7): 4192 - 4199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. van de Wetering, R. A. de Paus, J. T. van Dissel, and E. van de Vosse IL-23 modulates CD56+/CD3- NK Cell and CD56+/CD3+ NK-like T Cell function differentially from IL-12 Int. Immunol., February 1, 2009; 21(2): 145 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Guttman-Yassky, M. A. Lowes, J. Fuentes-Duculan, L. C. Zaba, I. Cardinale, K. E. Nograles, A. Khatcherian, I. Novitskaya, J. A. Carucci, R. Bergman, et al. Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis J. Immunol., November 15, 2008; 181(10): 7420 - 7427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Al-Salleeh and T. M. Petro Promoter Analysis Reveals Critical Roles for SMAD-3 and ATF-2 in Expression of IL-23 p19 in Macrophages J. Immunol., October 1, 2008; 181(7): 4523 - 4533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. de Beaucoudrey, A. Puel, O. Filipe-Santos, A. Cobat, P. Ghandil, M. Chrabieh, J. Feinberg, H. von Bernuth, A. Samarina, L. Janniere, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells J. Exp. Med., July 7, 2008; 205(7): 1543 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. McDuffie, N. A. Maybee, S. R. Keller, B. K. Stevens, J. C. Garmey, M. A. Morris, E. Kropf, C. Rival, K. Ma, J. D. Carter, et al. Nonobese Diabetic (NOD) Mice Congenic for a Targeted Deletion of 12/15-Lipoxygenase Are Protected From Autoimmune Diabetes Diabetes, January 1, 2008; 57(1): 199 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Noguchi, D. Wakita, M. Tajima, S. Ashino, Y. Iwakura, Y. Zhang, K. Chamoto, H. Kitamura, and T. Nishimura Blocking of IL-6 signaling pathway prevents CD4+ T cell-mediated colitis in a Th17-independent manner Int. Immunol., December 1, 2007; 19(12): 1431 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Annunziato, L. Cosmi, V. Santarlasci, L. Maggi, F. Liotta, B. Mazzinghi, E. Parente, L. Fili, S. Ferri, F. Frosali, et al. Phenotypic and functional features of human Th17 cells J. Exp. Med., August 6, 2007; 204(8): 1849 - 1861. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
